Mostrando 2 resultados de: 2
Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
ArticleAbstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advancPalabras claves:antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarkerAutores:Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania CrombetFuentes:scopusCIMAvax-EGF: A novel therapeutic vaccine for advanced lung cancer
ArticleAbstract: The results allowing the Cuban Regulatory Agency (CECMED) to grant the Sanitary Registration to thePalabras claves:cancer vaccine, CIMAvax-EGF, Fast-Track registration, NSCLC, Phase II-III clinical trialAutores:Arteaga N., Cuevas A., García Verdecia B., González G., Lage Davila A., Neninger Vinageras E., Rodríguez G., Tania Crombet, Viña L.Fuentes:scopus